10-K: Artivion Reports 2024 Results, Cites Cybersecurity Incident Impact

Artivion's 2024 results show revenue growth offset by a net loss, influenced by a cybersecurity incident and strategic investments.

Summary

• Artivion reported a 10% increase in revenue for the year ended December 31, 2024, reaching $388.5 million.
• Excluding foreign exchange effects, revenue increased by 9%.
• The revenue increase was driven by growth in aortic stent grafts, On-X products, surgical sealants, and preservation services.
• The company reported a net loss of $13.4 million for the year ended December 31, 2024.
• Research and development expenses were approximately $28.5 million, accounting for 7% of revenues.
• The company experienced a cybersecurity incident in the fourth quarter of 2024, which impacted revenue and incurred expenses.
• Artivion has $320.2 million of total nominal indebtedness outstanding as of December 31, 2024.
• The company believes that cash generated from operations, together with amounts available under the revolving credit facility, will be sufficient to meet working capital requirements and anticipated capital expenditures, and other strategic uses of cash, if any, and debt payments, if any, over the next twelve months.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While revenue increased, the net loss and the impact of the cybersecurity incident temper the positive aspects. The outlook is cautiously optimistic.

Positives

• Revenue increased by 10% compared to the previous year.
• Aortic stent grafts, On-X products, and surgical sealants all experienced revenue growth.
• The FDA granted HDE approval for use of AMDS in acute DeBakey Type I dissections in the presence of malperfusion.

Negatives

• The company reported a net loss of $13.4 million.
• The company experienced a cybersecurity incident in the fourth quarter of 2024, which impacted revenue and incurred expenses.
• Other revenues decreased 17% for the year ended December 31, 2024, as compared to the year ended December 31, 2023.

Risks

• The company's international operations are subject to various risks, including currency fluctuations and geopolitical conditions.
• The company faces intense competition in its market segments.
• The company is dependent on suppliers and contract manufacturers to provide quality products.
• The company is dependent on single and sole-source suppliers and single facilities.
• The company is dependent on its specialized workforce.
• The company may not realize all the anticipated benefits of its business development activities.
• Significant disruptions of information technology systems or breaches of information security systems could adversely affect the company's business.
• The company's business could be impacted by environmental, social, and governance matters.
• The company's products and tissues are highly regulated and subject to significant quality and regulatory risks.
• The company may be subject to fines, penalties, and other sanctions if it is deemed to be promoting the use of its products for unapproved, or off-label, uses.
• The company is subject to various US and international bribery, anti-kickback, false claims, privacy, transparency, and similar laws, any breach of which could cause a material, adverse effect on its business, financial condition, and profitability.
• United States policy changes may have a material, adverse effect on the company.
• As a medical device manufacturer and tissue services provider the company is exposed to risk of product liability claims and its existing insurance coverage may be insufficient, or it may be unable to obtain insurance in the future, to cover any resulting liability.
• Failure to comply with data privacy and security laws could have a material adverse effect on the company.
• The agreements governing the company's indebtedness contain restrictions that limit its flexibility in operating its business.
• The company's business could be negatively impacted as a result of stockholder activism.
• The company does not anticipate paying any dividends on its common stock for the foreseeable future.
• Provisions of Delaware law and anti-takeover provisions in the company's organizational documents may discourage or prevent a change of control, even if an acquisition would be beneficial to stockholders, which could affect the company's share price adversely and prevent attempts by stockholders to remove current management.

Future Outlook

The company believes that cash generated from operations, together with amounts available under the revolving credit facility, will be sufficient to meet working capital requirements and anticipated capital expenditures, and other strategic uses of cash, if any, and debt payments, if any, over the next twelve months.

Industry Context

The medical device industry is highly competitive and affected by new product introductions and activities of other industry participants, including the introduction of novel products and therapies aimed at unrelated disease states or even overall patient health.

Comparison to Industry Standards

• The document mentions several competitors including Baxter, Ethicon, Medtronic, Abbott Laboratories, Edwards Lifesciences, C.R. Bard, Integra Life Sciences, LifeNet, Corcym, Anteris Technologies, Elutia, Cook Medical, Gore & Associates, Terumo, LeMaitre Vascular, Maquet, Pfizer, and BioCer Entwicklungs-GmbH.
• These companies compete with Artivion in various product lines, including aortic stent grafts, surgical sealants, On-X products, and tissue preservation services.
• The document does not provide specific comparisons of Artivion's financial results to those of its competitors, but it does note that several competitors have greater financial and other resources for research and development, commercialization, acquisitions, and litigation.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the impact of the cybersecurity incident.
• Employees may be affected by the company's efforts to improve its cybersecurity infrastructure.
• Customers may experience disruptions in service due to the cybersecurity incident.

Next Steps

• The company will continue to work with its insurer to recoup covered losses from the cybersecurity incident.
• The company will continue to invest in its information technology and information security systems and employee information security training.
• The company will continue to pursue PMA approval for AMDS, which is anticipated in 2026.

Key Dates